Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.380
-0.080 (-5.48%)
At close: Apr 28, 2026, 4:00 PM EDT
1.460
+0.080 (5.80%)
Pre-market: Apr 29, 2026, 6:51 AM EDT
Invivyd Revenue
In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth. Invivyd had revenue of $17.21M in the quarter ending December 31, 2025, with 24.51% growth.
Revenue (ttm)
$53.43M
Revenue Growth
+110.47%
P/S Ratio
7.30
Revenue / Employee
$437,918
Employees
122
Market Cap
390.27M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 216.11M |
| Ginkgo Bioworks Holdings | 170.16M |
| Niagen Bioscience | 129.42M |
| Century Therapeutics | 109.16M |
| Neurogene | 925.00K |
| vTv Therapeutics | 17.00K |
IVVD News
- 9 days ago - Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit - GlobeNewsWire
- 19 days ago - Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program - Benzinga
- 19 days ago - Invivyd Transcript: Study update - Transcripts
- 20 days ago - Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles - GlobeNewsWire
- 23 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Invivyd Announces Presentation at the World Vaccine Congress Washington - GlobeNewsWire
- 7 weeks ago - Invivyd Earnings Call Transcript: Q4 2025 - Transcripts
- 7 weeks ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire